Literature DB >> 890014

HPLC determination of daunorubicin and daunorubicinol in human plasma.

R Hulhoven, J P Desager.   

Abstract

A high-performance liquid chromatographic method for the quantitative simultaneous measurement of daunorubicin and its active metabolite, daunorubicinol, at low concentrations in human plasma was described. The advantages of this method were specificity, sensitivity, minimal pre-analysis work-up and small sample size. The method was sensitive for plasma levels of daunorubicin and daunorubicinol as low as 10 ng/ml. Preliminary dosages on plasma from leukemic patients treated with a 4 hr infusion of 75 mg/m2 daunorubicin either as free drug or complexed with DNA were reported. The results suggested a slower disposition of the daunorubicin-DNA complex.

Entities:  

Mesh:

Substances:

Year:  1977        PMID: 890014

Source DB:  PubMed          Journal:  Biomedicine        ISSN: 0300-0893


  5 in total

1.  Daunorubicin-DNA complex in acute nonlymphoblastic leukemia.

Authors:  R Hulhoven; C Harvengt
Journal:  Cancer Chemother Pharmacol       Date:  1982       Impact factor: 3.333

2.  Human pharmacokinetics of the daunorubicin-DNA complex. An alternative view of the lysosomotropic theory.

Authors:  R Hulhoven; G Sokal; C Harvengt
Journal:  Cancer Chemother Pharmacol       Date:  1979       Impact factor: 3.333

Review 3.  Anthracycline antitumour agents. A review of physicochemical, analytical and stability properties.

Authors:  J Bouma; J H Beijnen; A Bult; W J Underberg
Journal:  Pharm Weekbl Sci       Date:  1986-04-25

4.  Pharmacokinetics of daunorubicin after administration as free drug or as DNA complex in leukemic patients.

Authors:  S O Nilsson; B Andersson; S Eksborg; M Beran; H Ehrsson
Journal:  Cancer Chemother Pharmacol       Date:  1981       Impact factor: 3.333

5.  Clinical trials with daunorubicin-DNA and adriamycin-DNA in acute lymphoblastic leukemia of childhood, acute nonlymphoblastic leukemia, and bronchogenic carcinoma.

Authors:  A Ferrant; R Hulhoven; A Bosly; G Cornu; J L Michaux; G Sokal
Journal:  Cancer Chemother Pharmacol       Date:  1979       Impact factor: 3.333

  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.